A randomized, double-blind, placebo-controlled, crossover study to evaluate the effects of morning administration of GW679769 [casopitant] (10mg and 30mg) on polysomnograph sleep recordings, subjective sleep assessment, daytime cognition and psychomotor function in subjects with primary insomnia.

Trial Profile

A randomized, double-blind, placebo-controlled, crossover study to evaluate the effects of morning administration of GW679769 [casopitant] (10mg and 30mg) on polysomnograph sleep recordings, subjective sleep assessment, daytime cognition and psychomotor function in subjects with primary insomnia.

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2015

At a glance

  • Drugs Casopitant (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 15 Oct 2010 Actual initiation date changed from 1 Mar 2006 to 1 May 2006 as reported by ClinicalTrials.gov.
    • 01 Oct 2010 Actual end date ( Jul 2007) added as reported by ClinicalTrials.gov.
    • 07 Dec 2007 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top